Bullish
Johnson & Johnson, a Dividend King, has maintained a 64-year streak of annual dividend increases, showcasing its resilience through significant challe...
Bullish
Johnson & Johnson (NYSE:JNJ) presented significant clinical trial results at ASCO 2026 covering autoimmunity, oncology, and myeloma, with promising da...
Bullish
A jury in Los Angeles, California found Johnson & Johnson (JNJ) not negligent in a talc-related cancer lawsuit. The lawsuit was brought by families of...
Bullish
Pinebridge Investments LLC has made a new investment of $50.20 million in Johnson & Johnson, acquiring 242,556 shares in the fourth quarter. This come...
Bearish
A former FDA commissioner testified in an ovarian cancer trial against Johnson & Johnson, alleging the company altered asbestos test results for its t...
Johnson & Johnson (JNJ) has seen a significant 52% one-year surge but has recently slipped slightly, prompting a reassessment of its current valuation...
Bullish
Total Wealth Planning & Management Inc. initiated a new position in Johnson & Johnson (JNJ) during the fourth quarter, acquiring 4,997 shares valued a...
Newsweek, in partnership with Plant-A Insights Group, has released its "World’s Greenest Companies 2026" list, recognizing 850 companies across 28 cou...
Johnson & Johnson (NYSE:JNJ) announced positive topline Phase 2 results for nipocalimab in systemic lupus erythematosus (SLE) and Sjögren's disease, w...
Bullish
Johnson & Johnson announced positive late-breaking phase 2 results for nipocalimab in adults with moderate to severe systemic lupus erythematosus (SLE...
Bearish
The FDA has issued an early alert regarding a higher-than-expected rate of thrombus formation associated with specific 14Fr low-profile introducer kit...
Bullish
Johnson & Johnson is a leading developer of multiple myeloma therapies, with the aspirational goal of making the disease curable in the near future. D...
Bullish
Johnson & Johnson (JNJ) announced late-stage clinical trial results for its prostate cancer drug apalutamide. The study found that combining apalutami...
Bullish
Johnson & Johnson's prostate cancer drug Erleada, when used with hormone-blocking therapy before and after surgery, significantly reduced the risk of ...
Johnson & Johnson's Erleada (apalutamide) achieved a significant phase 3 win in the Proteus study for high-risk localized or locally advanced prostate...
Bullish
Welch & Forbes LLC slightly decreased its stake in Johnson & Johnson by 0.9% in Q4, holding 670,094 shares valued at $138.7 million. Johnson & Johnson...
Neutral
Northwestern Mutual Wealth Management Co. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 2.7% in the 4th quarter, a...
Pfizer's Talzenna, in combination with Xtandi, has achieved a significant phase 3 win in metastatic castration-sensitive prostate cancer (mCSPC), demo...
Bullish
CNBC's Squawk Box conducted a full interview with Johnson & Johnson Chairman and CEO Joaquin Duato. The discussion covered key topics including the co...
Dizal Pharma's Zegfrovy shows promising results in a Phase 3 trial for first-line treatment of advanced non-small cell lung cancer with EGFR exon 20 i...